Key Highlights
- Patrick Machado, J.D., brings 20+ years of biotech leadership experience to Avenzo Therapeutics.
- Former co-founder of Medivation, Inc., contributing to its $14B acquisition by Pfizer.
- Avenzo’s lead drug, AVZO-021, targets advanced solid tumors and metastatic breast cancer.
Source: Business Wire
Notable Quotes
- “Pat has extensive experience leading and working with biotech companies around the world, and I am excited to welcome him to our board.” – Athena Countouriotis, M.D., Co-founder, President, and CEO at Avenzo
- “I look forward to working with my fellow board members and the executive team to advance the company’s growth and potentially bring new treatment options to cancer patients.” – Patrick Machado, J.D., Board Member at Avenzo
SoHC's Take
The addition of Patrick Machado to Avenzo Therapeutics’ board signifies a strategic move to leverage Machado’s extensive industry experience in scaling biotech organizations. Known for his role in Medivation’s blockbuster success and subsequent acquisition by Pfizer, Machado’s insights will be instrumental as Avenzo advances its promising oncology pipeline, including its innovative CDK2 inhibitor, AVZO-021. His proven track record in corporate strategy and oncology development aligns seamlessly with Avenzo’s mission to address unmet medical needs in cancer treatment.
